CERO THERAPEUTICS HOLDINGS, INC.

Cero Therapeutics Holdings, Inc. (Nasdaq: CERO) is a clinical-stage biopharmaceutical company focused on chimeric engulfment receptor T-cell (CER-T) therapies for oncology indications. The company became publicly listed through its de-SPAC merger with Phoenix Biotech Acquisition Corp. (Nasdaq: PBAX), a blank-check vehicle sponsored by Phoenix Biotech Sponsor LLC that completed its IPO in 2021. The transaction closed in early 2024, bringing CERO into the public markets within the biotechnology and cell-therapy sector. The company filed an 8-K current report with the SEC on August 31, 2026, under accession number 0001213900-26-095776, reflecting its ongoing public reporting obligations as a post-combination entity. For comprehensive filing history, deal terms, and real-time SPAC analytics on CERO and hundreds of other transactions, sign up for full data access at SpacDesk.